Use of Antibody Cocktail, REGN-COV2, in two Non-Hodgkin’s Lymphoma (NHL) patients with mild COVID-19 disease, at a tertiary care hospital in South India: A case series

Authors

  • Anita Ramesh Senior Consultant Medical Oncologist, Kauvery Hospital, Chennai, Tamilnadu, India
  • Andrew C. Fenn Consultant Radiation Oncologist, Kauvery Hospital, Chennai, Tamilnadu, India
  • Sivaram Kannan Senior Consultant Internal Medicine & Diabetology, Kauvery Hospital, Chennai, Tamilnadu, India
  • Ezhilan Naganathan Consultant Physician and Diabetologist, Kauvery Hospital, Chennai, Tamilnadu, India

Keywords:

SARS–CoV-2, Corona, COVID, REGN-COV2, Non-Hodgkin’s Lymphoma, antibody cocktail

Abstract

Severe Acute Respiratory Syndrome Corona virus 2 (SARS–CoV-2) is the cause for Corona virus disease 2019 (COVID-19). Most patients have asymptomatic or mild disease. A subset of patients develops moderate, severe or critical disease. The prognosis is dismal with
severe and critical disease. REGN-COV2 has been shown to reduce the progression to severe disease in high-risk subjects, by reducing the viral load in the early stages of the illness. We describe two patients with Non-Hodgkin’s Lymphoma and COVID 19, who received
the antibody cocktail, and did not develop severe disease.

Downloads

Published

2024-05-31

How to Cite

Anita Ramesh, Andrew C. Fenn, Sivaram Kannan, & Ezhilan Naganathan. (2024). Use of Antibody Cocktail, REGN-COV2, in two Non-Hodgkin’s Lymphoma (NHL) patients with mild COVID-19 disease, at a tertiary care hospital in South India: A case series. Kauverian Medical Journal, 1(7), 5–7. Retrieved from https://kauverianjournal.com/index.php/research/article/view/32

Issue

Vol. 1 No. 7 (2024): May

Section

Articles